Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
30 Oct 2018  |  Africa
Unlocking Investment Potential and Improving Healthcare Delivery and Access through Policy Advancement
The East African region boasts of a number of emerging leaders within Sub-Saharan Africa in terms of overall development and growth. On one hand, the region has one of the highest burdens of disease in the world, such as HIV, malaria, and tuberculosis. On the other hand, there has been a growing trend of non-communicable diseases, such as cancers a...
24 Oct 2018  |  North America
A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market
The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...
22 Oct 2018  |  North America
Digitalization and M&As to Transform the Current Competitive Structure of the Industry
The global life sciences instrumentation and research tools market is currently going through a transformation driven by ongoing market consolidation and technological innovation. Over the past five years, the industry has witnessed more than 50 mergers and acquisitions (M&A), which have resulted in a market consolidation at the top. Most of these ...
05 Oct 2018  |  North America
CLIA Waived Molecular POCT, Coupled with Upcoming Diseases Like Sepsis, Lyme Disease, New Strains of Influenza—H1, H3, and H7, will Drive Growth
Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...
28 Sep 2018  |  North America
A new wave of gene therapies is set to revolutionize treatments over the next decade for inherited diseases which are either untreatable or which do not have a satisfactory treatment outcome at present
The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...
04 Sep 2018  |  North America
Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities
The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally ...
27 Aug 2018  |  Global
Consumer Education and Exploring Alternative Markets Would Drive the Direct-to-Consumer Genetic Testing Market
As healthcare evolves toward personalized solutions, everyday consumers are proactively taking responsibility for their health in ways unimaginable a decade ago. A direct-to-consumer genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider....
23 Aug 2018  |  Europe
Clinical Labs to Transform into Health Information Companies and Increasingly Participate in Clinical Decision Support
Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards cre...
18 Jul 2018  |  Global
Medical Cannabis Revenue will Overtake Recreational in the Next 4 Years
The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal le...
05 Jul 2018  |  Global
Synopsis from World Café Discussions Held at Health IT Forum of Medica 2017
Healthcare organizations face numerous challenges in today’s dynamic business environment, be it clinical, non-clinical or operational processes in hospitals. The industry is fundamentally focusing on digital transformational strategies, while increasing its investments in next-generation solutions such as clinical information systems, connected ...